Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

228
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
228

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.

HemaSphere·2026
Same author

Association Between Obesity and Sex-Related Survival Difference in Lung Cancer.

JCO clinical cancer informatics·2026
Same author

Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

Molecular oncology·2026
Same author

Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients.

HemaSphere·2026
Same author

Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
Same journal

Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

Clinical pharmacology and therapeutics·2026
Same journal

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

Clinical pharmacology and therapeutics·2026
Same journal

Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries.

Clinical pharmacology and therapeutics·2026
Same journal

Quantitative Systems Toxicology Model Predicts Obeticholic Acid-Associated Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Clinical pharmacology and therapeutics·2026
Same journal

Genetic Determinants of Treatment-Related Bone Toxicity in Pediatric Acute Lymphoblastic Leukemia.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.3K

Enhancing Severe Neutropenia Prediction: PKPD-Informed Labeling for Machine Learning Models Trained on Real-World

Conor J O'Hanlon1,2, Jonas Denck1, Elif Ozkirimli1

  • 1Roche Informatics, F. Hoffmann-La Roche AG, Kaiseraugst, Switzerland.

Clinical Pharmacology and Therapeutics
|November 10, 2025
PubMed
Summary
This summary is machine-generated.

A new pharmacokinetic-pharmacodynamic (PKPD)-informed labeling strategy significantly improves machine learning models for predicting docetaxel-induced neutropenia risk. This method enhances data quality and quantity, overcoming real-world data challenges.

More Related Videos

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
09:53

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography

Published on: August 16, 2020

7.6K

Related Experiment Videos

Last Updated: Jan 11, 2026

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
07:15

Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model

Published on: August 16, 2020

7.3K
Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.6K
Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography
09:53

Quantifying the Brain Metastatic Tumor Micro-Environment using an Organ-On-A Chip 3D Model, Machine Learning, and Confocal Tomography

Published on: August 16, 2020

7.6K

Area of Science:

  • Pharmacology and Machine Learning
  • Clinical Data Science
  • Computational Biology

Background:

  • Real-world data (RWD) labeling for machine learning (ML) is hindered by sparsity and imbalances.
  • Accurate prediction of docetaxel-induced neutropenia is crucial for patient safety.
  • Existing methods struggle with the nuances of RWD for predictive modeling.

Purpose of the Study:

  • To develop and evaluate a pharmacokinetic-pharmacodynamic (PKPD)-informed labeling strategy.
  • To enhance the risk prediction of docetaxel-induced neutropenia using ML.
  • To address data sparsity and imbalance issues in RWD for clinical outcome prediction.

Main Methods:

  • Developed a PKPD-informed labeling strategy using semi-mechanistic model simulations to determine neutrophil nadir.
  • Trained three ML models (logistic regression, XGBoost, TabPFN) on RWD from 4,248 patients.
  • Compared PKPD-informed labeling against a naive labeling method using only neutrophil observations.

Main Results:

  • The PKPD labeling approach increased labeled patient instances by 3.4 times (7,719 vs. 2,283).
  • ML models trained with PKPD-informed labels showed significantly superior predictive performance (AUC-ROC, AUC-PR) across all architectures.
  • Performance gains were consistent even when training set sizes were matched.

Conclusions:

  • PKPD-informed labeling effectively overcomes RWD sparsity and imbalance limitations.
  • This strategy enhances both the quantity and quality of labels for ML model training.
  • The methodology provides a robust and generalizable framework for improving clinical outcome prediction in ML.